Palisade Bio(US:PALI) Globenewswire·2026-01-16 13:30Core Insights - Palisade Bio, Inc. is advancing its lead program, PALI-2108, a gut-targeted PDE4 inhibitor for ulcerative colitis, with two abstracts selected for presentation at major IBD conferences in early 2026 [1][3][4] Group 1: Product Development - PALI-2108 is designed for local delivery of PDE4 inhibition specifically to the terminal ileum and colon, minimizing systemic exposure and enhancing therapeutic index [4][7] - The prodrug is activated in the lower intestine, allowing for sustained local exposure and once-daily dosing, which aims to improve tolerability compared to systemic PDE4 inhibitors [4][7] - In a Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis cohort, with no serious adverse events reported [7] Group 2: Clinical Engagement - The Crohn's & Colitis Congress 2026 will feature a poster presentation on PALI-2108's ability to restore immune-epithelial balance in ulcerative colitis [2] - The 21st Congress of ECCO will also showcase findings from a Phase 1a study demonstrating clinical, histologic, and biomarker improvements with PALI-2108 [3] - The company aims to engage with the global IBD community to discuss these findings and the potential of PALI-2108 [3] Group 3: Future Plans - Palisade Bio is preparing to initiate a Phase 2 clinical study in ulcerative colitis, focusing on clinical remission and pharmacodynamic biomarkers over a 12-week period [8] - The company is also planning studies in fibrostenotic Crohn's Disease to further evaluate PALI-2108's safety and therapeutic benefits [8]